FDA to Restrict Use of Regeneron, Lilly COVID Antibody Drugs

Published on January 24, 2022

The U.S. Food and Drug Administration (FDA) is likely to restrict the use of COVID-19 antibody treatments from Regeneron and Eli Lilly as they are ineffective against the omicron variant, the Washington Post reported on Monday. The FDA action will involve revising the…

Read Full Article (External Site)